Sign in Subscribe
Cancer research

Overexpression of Protein Kinase C iota as a Prognostic Marker in Colon Cancer

Strategic Insights

— 1 min read

Researchers at Sun Yat-sen University have found that overexpression of protein kinase C iota (PKCi) is associated with tumor aggressiveness and chemotherapy resistance in patients with colorectal cancer. In a retrospective analysis of patients with confirmed cancer diagnoses, the team found that PKCi overexpression was correlated with advanced clinical stage, metastasis, organs involvement, vascular invasion, and perineural invasion. Patients with PKCi overexpression also exhibited significantly shorter progression-free survival compared to those with low expression levels.

Key Takeaways:

  • PKCi overexpression is associated with tumor aggressiveness and chemotherapy resistance in colorectal cancer patients.
  • PKCi overexpression is correlated with advanced clinical stage, metastasis, organs involvement, vascular invasion, and perineural invasion.
  • Patients with PKCi overexpression exhibit significantly shorter progression-free survival compared to those with low expression levels.
  • The study found that PKCi overexpression is an independent prognostic factor for overall survival and progression-free survival.
  • PKCi overexpression is possibly correlated with oxaliplatin resistance, with a P-value of 0.014.
  • Univariate Cox analysis confirmed that metastasis and clinical staging are independent prognostic factors for overall survival, while CEA levels are independent predictors of progression-free survival.

Statistics:

  • 11.910 (HR) and P = 0.018 for metastasis as an independent prognostic factor for overall survival.
  • 5.498 (HR) and P = 0.027 for clinical staging as an independent prognostic factor for overall survival.
  • 3.497 (HR) and P = 0.005 for CEA levels as an independent predictor of progression-free survival.
  • PKCi overexpression was observed in 45% of patients with colorectal cancer.
  • Patients with PKCi overexpression exhibited significantly shorter progression-free survival (PFS) compared to those with low expression levels (P = 0.0006).

Sources:

  • Overexpression of Protein Kinase C iota as a prognostic marker and its role in oxaliplatin resistance in colorectal cancer. BMC Gastroenterology, 2025,25(1):1-11. (BMC Gastroenterology - http://bmcgastroenterol.biomedcentral.com)
  • Xuankai Liao, Department of Pathology, Seventh Affiliated Hospital, Sun Yat-sen University.

Read more